Досвід застосування препарату «Пентотрен» у пацієнтів з облітерувальними захворюваннями периферичних артерій

The aim  — to improve the treatment results of patients with obliterating atherosclerosis of the arteries of the lower extremities. Materials and methods. The examination and treatment results of 50 patients aged 45 to 80 years with stable intermittent claudication (Fontaine 2) without exacerbations during the last 6 months, confirmed by ultrasonic duplex scanning data, computed tomography with angiography or arteriography, were analysed. Patients were divided into two groups. Patients of the main group (n = 30) received treatment with Pentotren (Darnitsa, soluble form of pentoxifylline 0.5 mg/ml, 200 ml in a vial) 3 vials twice a day, infusion rate 100 mg/h. The program of physical activity was recommended. Patients of the control group (n = 20) were treated with 600 ml of physiological solution twice a day with maximum physical activity. Duration of treatment was 14 days. Results and discussion. The use of the ready­made infusion form of pentoxifylline in a daily dose of 600 mg in combination with physical exercises under the physician supervision and risk factors correction allowed to increase the painless walking distance by 71.8 % and the maximum walking distance by 78.3 %, which improved quality of patients’ life. Conclusions. The data obtained make it possible to recommend the pentoxifylline medication in the complex treatment of occlusive atherosclerotic diseases of peripheral arteries.